The Medical Letter on Drugs and Therapeutics
Sitagliptin and Simvastatin (Juvisync)
November 14, 2011 (Issue: 1377)The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).
2. Price according to drugstore.com. Accessed November 7, 2011.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.